TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Nosocomial Bacteremia Among Zambian Neonates

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Neonates admitted to the study site NICU during the study period (including both inborn and outborn neonates)~Exclusion Criteria:~* Neonates without documented birth date~* Parent or guardian unavailable or unwilling to provide consent

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Infection control package consisting of alcohol hand rub hand hygiene (HH), 2% chlorhexidine gluconate (CHG) body washes, infection control training, and text messages with basic Infection control reminders via SMS text

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of photosensitive epilepsy~Exclusion Criteria:~- inconsistent photoparoxysmal response when stimulated by photic stimulation~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): None
- Cohort II (Type: EXPERIMENTAL): None
- Cohort III (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or females 12 years or older~* History of persistent bronchial asthma for at least 6 months~* Documented use of an inhaled steroid or a combination of an inhaled steroid/long-acting beta 2 agonist for at least 1 month before screening~* At screening, FEV1 of 60 to 90% predicted or 70 to 95% predicted for either ICS or ICS/LABA use respectively.Reversibility of FEV1 by at least 12% and 200 ml post-bronchodilator~* Be able to use oral inhalers~* Non-smokers~Exclusion Criteria:~* History of life-threatening asthma~* Other pulmonary diseases; URI within 4 weeks before screening~* Use of systemic steroids within 1 month before screening or more than 3 times in previous 6 months~* Beta-adrenergic blocking agent use~* More than 2 in-patient hospitalizations or ER visits due to asthma exacerbations in the prior year before screening~* Pregnant or breast-feeding females~* Females of child-bearing potential not using adequate means of birth control~* Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease~* Abnormal clinical laboratory parameters that would limit participation in the study or interfere with interpretation of study results~* History of drug or alcohol abuse~* Treatment with any investigational product within 30 days prior to study entry

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remifemin Preventing the Climacteric Symptoms in Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. provision of informed consent~2. clinical stage I\~IIIC~3. histologically proven invasive breast cancer~4. women defined as premenopausal according to NCCN guideline~5. plan to accept the LHRH-a as endocrine treatment or ovarian function protection~Exclusion Criteria:~1. clinical evidence of metastatic disease~2. bilateral oophorectomy~3. patients who, for whatever reason (e.g., confusion, infirmity, alcoholism), are unlikely to comply with trial requirements~4. patients who accepted anti-cancer treatment before~5. previous hormonal therapy as adjuvant treatment for non-cancer disease~6. patients unwilling to stop taking any drug known to affect sex hormonal status, or in whom it would be inappropriate to stop previous history of invasive malignancy within the last 5 years, other than squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix, adequately cone biopsied~7. treatment with a non-approved or experimental drug during 1 month before entry into the study~8. history of bleeding diathesis (i.e., Disseminated intravascular coagulation, clotting factor deficiency), or long term anticoagulant therapy (other than antiplatelet therapy and low dose warfarin)~9. leukopenia and/or thrombocytopenia~10. history of ocular fundus diseases~11. history of thromboembolic diseases~12. history of osteoporotic fractures

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Remifemin intervention (Type: EXPERIMENTAL): Using Remifemin during LHRH-a treatment in breast cancer
- Control (Type: NO_INTERVENTION): No intervention during LHRH-a treatment in breast cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* AIM 1 (SURVEY) (AIM 1 is closed to enrollment)~* Cancer survivor~* Between 12 and 60 months after completion of cancer therapy (chemotherapy, radiation, hematopoietic cell transplant \[HCT\])~* Scheduled for a return clinic visit at one of the participating institutions~* English or Spanish-speaking~* Willing to provide informed consent/assent for study participation~* AIM 2 (VACCINE EVALUATION)~* Meets all inclusion criteria outlined in Aim 1~* Survey response indicated no prior history of HPV vaccination OR patient has no prior history of HPV vaccination by self - or parent/caregiver-report~* English or Spanish-speaking~* Medical clearance from treating clinician for study participation~* Agrees to return to participating institution for 3 HPV vaccine injections~* Willing to provide informed consent/assent for study participation~Exclusion Criteria:~* AIM 2 (VACCINE EVALUATION)~* Allergy to any component of the HPV vaccine including yeast and aluminum~* Thrombocytopenia (platelet count \< 50K) or coagulation disorder that would contraindicate intramuscular injection~* Transfusion of blood products or intravenous immune globulin within 3 months of study entry~* Female, and a) currently pregnant or lactating, or b) of childbearing potential and unwilling to avoid pregnancy during the vaccine phase of study (beginning at Day 1 and continuing until at least 4 weeks after all 3 vaccine doses have been administered)

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 26 Years
- Healthy Volunteers: f

Study Arms:
- Prevention (vaccine therapy) (Type: EXPERIMENTAL): Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) or nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Assessed between 20 and 24 months of pregnancy~* Pregnancy known before 24 weeks of gestation~* Documented HIV-1 infection without indication for ARV therapy~* CD4 count above or equal to 350 per mm3~* VL under 30 000 copies per ml~* Naïve for PI (except treatment during previous pregnancy)~* Informed consent signed~Exclusion Criteria:~* HIV2 infection or HIV1 group O infection~* Any pathology related to pregnancy~* Contra-indication to study drugs~* Unstable hypertension or diabetes~* Known risk of premature delivery~* In case of previous treatment with a protease inhibitor : presence of resistance mutations on the HIV-1 protease gene by genotyping analysis (1 mutation among V32I et I47A, I50V V82A/F/S/T, I84V, L90 M or more than 3 mutations among L10 F/I/R/V, K20/M/R, L24I, L33F, M46I/L, F53L, I54M/L/T/V, L63P, A71L/V/T,)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Kaletra (lopinavir/ritonavir)
- 2 (Type: ACTIVE_COMPARATOR): Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AL-15469A for the Treatment of Bacterial Conjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* signs and symptoms of bacterial conjunctivitis~* Other protocol-defined inclusion criteria may apply~Exclusion Criteria:~* under 1 mo. age~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Moxifloxacin (Type: EXPERIMENTAL): None
- VIGAMOX (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Probiotic Lactobacilli for the Treatment of Lactational Mastitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of mastitis~* Staphylococcal and/or streptococcal count higher than 3000 colony-forming units per ml of milk~* Milk leukocyte count higher 6 log10/mL~* Must be able to provide a milk sample without the aid of a milk pump~Exclusion Criteria:~* Mammary abscesses~* Any kind of parallel disease

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Probiotic 1 (Type: EXPERIMENTAL): Women receiving Lactobacillus salivarius HN6
- Probiotic 2 (Type: EXPERIMENTAL): Women receiving Lactobacillus reuteri CR20
- Probiotic 3 (Type: EXPERIMENTAL): Women receiving Lactobacillus fermentum LC40
- beta-lactam (Type: ACTIVE_COMPARATOR): The evolution of the women ascribed to the other three arms will be compared with that of 100 women suffering lactational mastitis that will follow a conventional antibiotic treatment as prescribed by the pediatrician/gynecologist

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with chronic PTSD for six months or longer.~* Have a CAPS score showing moderate to severe PTSD symptoms.~* At least one unsuccessful attempt at treatment for PTSD either with talk therapy or with drugs, or discontinuing treatment because of inability to tolerate psychotherapy or drug therapy.~* Are at least 18 years old.~* Must be generally healthy.~* Are willing to refrain from taking any psychiatric medications during the study period.~* Willing to follow restrictions and guidelines concerning consumption of food, beverages or nicotine the night before and just prior to each MDMA session.~* Willing to remain overnight at the study site.~* Are willing to be driven home after experimental sessions either by a driver they arrange, a taxi, or study personnel.~* Are willing to be contacted via telephone by study personnel.~* If of child-bearing age, must have a negative pregnancy and agree to use an effective form of birth control.~* Must provide a personal contact who is willing to be reached in case of emergency.~* Agree to let the investigators know within 48 hours of any planned medical interventions.~* Are proficient in reading and speaking English.~* Agree to have all psychotherapy sessions recorded.~* Agree not to participate in any other interventional clinical trials during the course of the study.~Exclusion Criteria:~* Are pregnant or nursing, or if of child-bearing age and do not use an effective means of birth control.~* Weigh less than 48 kg.~* Are abusing illegal drugs.~* Are unable to give adequate informed consent.~* Upon review of past and current drugs/medication, must not be on or have taken a medication that is exclusionary.~* Upon review of medical or psychiatric history, must not have any current or past diagnosis that would be considered a risk to participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Comparator-dose (40 mg) MDMA and Psychotherapy (Type: ACTIVE_COMPARATOR): Participants receive an initial dose of comparator-dose MDMA (40 mg) during each of the two experimental sessions.
- Active Dose 2 (100 mg) MDMA and Psychotherapy (Type: EXPERIMENTAL): Participants receive an initial dose of Active Dose 2 MDMA (100 mg) during each of the two experimental sessions.
- Active Dose 1 (125 mg) MDMA and Psychotherapy (Type: EXPERIMENTAL): Participants receive an initial dose of Active Dose 1 MDMA (125 mg) during each of two experimental sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical signs of WHO-defined severe pneumonia~* Age 2 months to 59 months~Exclusion Criteria:~* Clinical signs of WHO-defined very severe pneumonia~* Clinical or laboratory diagnosis of meningitis~* Clinical diagnosis of severe malnutrition (marasmus/kwashiorkor)~* Clinical or laboratory diagnosis of severe anaemia requiring transfusion~* HIV-exposure on rapid HIV antibody test (only observational data will be collected from these patients)~* Elimination of signs of severe pneumonia in a child with wheeze after outpatient bronchodilator therapy~* Chronic condition that may underlie or contribute to a presentation with respiratory distress such as: known chronic renal or cardiac disease, presence of cerebral palsy predisposing child to aspiration/hypostatic pneumonia~* Established bronchiectasis or congenital abnormality of the lower respiratory tract~* Upper airway obstruction producing stridor~* Admission from outpatient clinic specifically for treatment of TB~* Referral from another inpatient facility following treatment with injectable antibiotics for more than 24 hours or because the initial regimen is considered to have failed~* Documented history of \>48hours treatment with oral amoxicillin~* Failure to obtain informed consent~* Penicillin allergy

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Amoxicillin 45mg/kg 12 hourly (Type: EXPERIMENTAL): None
- Benzyl Penicillin 50,000IU/kg 6 hourly (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Local Effect and Safety of a Single PPC-5650 Dose on Reflux Pain During Pain Stimulation in the Esophagus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent before any study specific procedures~* Able to read and understand Danish.~* Healthy i.e. no history of chronic or recurrent pain rewarding diseases~* Able to co-operate and tolerate the experimental procedures (as assessed in the training visit)~* No over the counter medication 24h before the three visits~* No medications in the study period~* BMI 18.5-35.0~* Caucasian~* No symptoms of Gastroesophageal reflux disease~* All men must use a safe method of contraception during the study period~Exclusion Criteria:~* Any clinically relevant abnormal values from the laboratory tests on hematology, clinical chemistry, and/or urine analyses, as judged by the investigator.~* Participation in any other clinical trial within three months prior to the training day.~* Alcohol or drug abuse.~* Mental illnesses~* Allergic to the active ingredient in the investigational medicinal product

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Placebo solution (Type: PLACEBO_COMPARATOR): A 100 ml placebo solution will be administered through an esophageal probe. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with placebo in one out of three visit days.
- PPC-5650 (Type: ACTIVE_COMPARATOR): PPC-5650 is a asic-sensing ion channel-1a antagonist that can block the acid-sensing ion channels, leading to a reduction in the pain signal under up-regulated conditions. A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered through an esophageal probe to assess local effects. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with PPC-5650 in one out of three visit days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Body Mass index ≥ 27 kg/m2~* Albuminuria ≥ 30 mg/g and ≤ 3500 mg/g~* eGFR ≥ 25 ml/min/1.73m2~* Stable renal function prior to entry into the study defined as no more than 30% eGFR change in 3 months prior to enrolment~* Signed Informed Consent~Exclusion Criteria:~* Diagnosis with type 1 or type 2 Diabetes~* Hba1c ≥ 6.5% at screening~* Cardiovascular disease event in 3 months prior to enrollment~* Treatment with GLP-1 RA \< 4 weeks prior to screening~* Uncontrolled thyroid disease TSH\>6.0 mIU/L or \<0.4 mIU/L at screening~* Acute pancreatitis \< 180 days prior to screening~* History or presence of chronic pancreatitis~* Females of child-bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Patients will be treated with semaglutide 3 mg/ml s.c. once weekly for 24 weeks. The starting dose of semaglutide will be 0.24 mg subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg once weekly.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive a matching placebo s.c. once weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete